Skip to main content
SpringerLink
Log in

Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Block A. Costs and benefits of direct-to-consumer advertising: the case of depression. Pharmacoeconomics 2007; 25 (6): 511–521

    Article  PubMed  Google Scholar 

  2. Iizuka T, Jin GZ. The effect of prescription drug advertising on doctor visits. J Econ Manag Strategy 2005; 14 (3): 701–727

    Article  Google Scholar 

  3. Weissman JS, Blumenthal D, Silk AJ, et al. Consumers’ reports on the health effects of direct-to-consumer drug advertising. Health Aff (Millwood) 2003 Jan–Jun; Suppl Web Exclusives: W3-82-95

    Google Scholar 

  4. Degner D, Grohman R, Kropp S, et al. Severe adverse drug reactions of antidepressants results of the German MultiCenter Drug Surveillance Program AMSP. Pharmacopsychiatry 2004; Suppl. 1: S39–S45

    Google Scholar 

  5. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40

    Article  PubMed  Google Scholar 

  6. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000. Summary: advance data from vital and health statistics. CDC June 5, 2002. Number 328: 1–32 [online]. Available from URL: http://www.cdc.gov/nchs/data/ad/ad 328.pdf [Accessed 2008 Jun 4]

    PubMed  Google Scholar 

  7. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289: 3095–3105

    Article  PubMed  Google Scholar 

  8. Wakefield JC, Schmitz MF, First MB, et al. Extending the bereavement exclusion for major depression to other losses: evidence from the National Comorbidity Survey. Arch Gen Psychiatry 2007 Apr; 64 (4): 433–440

    Article  PubMed  Google Scholar 

  9. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 Feb; 5 (2): e45

    Article  PubMed  Google Scholar 

  10. Patten SB. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Popul Health Metr 2004 Nov 1; 2 (1): 9

    Article  PubMed  Google Scholar 

  11. The Henry J. Kaiser Family Foundation. Understanding the effects of direct-to-consumer prescription drug advertising. Menlo Park (CA): The Henry J. Kaiser Family Foundation, November 2001 [online]. Available from URL: http://www.kf f.org/rxdrugs/upload/Understanding-the-Effects-of-Direct-to-Consumer-Prescription-Drug-Advertising-Report.pdf [Accessed 2008 Feb 18]

    Google Scholar 

  12. Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 2006; 3 (4): el98

    Article  Google Scholar 

  13. United States Government Accountability Office. Prescription drugs: improvements needed in FDA’s oversight of direct-to-consumer advertising. Washington, DC: United States Government Accountability Office, 2006 [online]. Available from URL: http://frwebgate.access.gpo gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.183&filename=d0754.pdf&directory=/dis ka/wais/data/gao [Accessed 2008 Mar 26]

    Google Scholar 

  14. National Institute for Health and Clinical Excellence. Depression: management of depression in primary and secondary care [clinical guideline 23]. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG 23quickrefguideamended.pdf [Accessed 2008 Mar 20]

    Google Scholar 

  15. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment on the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389–395

    Article  PubMed  CAS  Google Scholar 

  16. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005 Apr 27; 293: 1995–2002

    Article  PubMed  CAS  Google Scholar 

  17. Aikin KJ. Direct-to-consumer advertising of prescription drugs: physician survey preliminary results. Rockville (MD): US Food and Drug Administration, 2003 [online]. Available from URL: http://www.fda.gov/cder/ddmac/globalsummit2003 [Accessed 2008 Jun 1]

    Google Scholar 

  18. Frank RG, McGuire TG, Normand SL, et al. The value of mental health care at the system level: the case of treating depression. Health Aff (Millwood) 1999; 18: 71–88

    Article  CAS  Google Scholar 

  19. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005; 3: 449–456

    Article  PubMed  Google Scholar 

  20. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252–260

    Article  PubMed  CAS  Google Scholar 

  21. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depresison in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008; 178: 296–305

    PubMed  Google Scholar 

  22. Goldberg D, Privett M, Ustun B, Simon G, Linden M. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Br J Gen Pract 1998 48: 1840–1844

    PubMed  CAS  Google Scholar 

  23. Ronalds C, Creed F, Stone K, et al. Outcome of anxiety and depressive disorders in primary care. Br J Psychiatry 1997 Nov; 171: 427–433

    Article  PubMed  CAS  Google Scholar 

  24. Brugha TS, Bebbington PE, MacCarthy B, et al. Antidepressants may not assist recovery in practice: a naturalistic prospective survey. Acta Psychiatr Scand 1992 Jul; 86 (1): 5–11

    Article  PubMed  CAS  Google Scholar 

  25. Healy D, Alfred G. Antidepressant drug use and the risk of suicide. Int Rev Psychiatry 2005; 17: 163–172

    Article  PubMed  Google Scholar 

  26. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396–402

    Article  PubMed  CAS  Google Scholar 

  27. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911–932

    Article  PubMed  Google Scholar 

  28. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000 May 2; 132 (9): 743–756

    PubMed  CAS  Google Scholar 

  29. Gartlehner G, Hansen RA, Kahwati L, et al. Drug class review on second generation antidepressants. Drug Effectiveness Review Project. Sept 2006 [online]. Available from URL: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm [Accessed 2008 Mar 20]

    Google Scholar 

  30. Lima MS, Moncrieff J. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev 2000; (4): CD001130

    Google Scholar 

  31. Montego AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001; (62 Suppl. 3): 10–21

    Google Scholar 

  32. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998 Jul 15; 44 (2): 77–87

    Article  PubMed  CAS  Google Scholar 

  33. Bogetto F, Bellino S, Revello RB, et al. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002; 16 (4): 273–283

    Article  PubMed  CAS  Google Scholar 

  34. Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006; 20 (2): 143–151

    Article  PubMed  Google Scholar 

  35. Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67 Suppl. 4: 27–30

    PubMed  CAS  Google Scholar 

  36. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004 60: 57–61

    Article  PubMed  Google Scholar 

  37. Runé HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006 Dec; 67 (12): 1836–1855

    Article  Google Scholar 

  38. Rascati K, Godley P, Pham H. Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. J Manag Care Pharm 2001 Sep–Oct; 7 (5): 402–406

    Google Scholar 

  39. Iqbal SU, Prashker M. Pharmacoeconomic evaluation of antidepressants: a critical appraisal of methods. Pharmacoeconomics 2005; 23 (6): 595–606

    Article  PubMed  CAS  Google Scholar 

  40. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008 Jan; 165 (1): 42–50

    Article  PubMed  Google Scholar 

  41. Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom Med 1998; 60: 143–149

    Google Scholar 

  42. Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998 Jul; 55 (7): 645–651

    Article  PubMed  CAS  Google Scholar 

  43. Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1999

    Google Scholar 

  44. Mclntyre RS, O’Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry 2004 Mar; 49 (3 Suppl. 1): 10S–16S

    Google Scholar 

  45. Spijker J, de Graaf R, Bijl RV, et al. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002 Sep; 181: 208–213

    Article  PubMed  Google Scholar 

  46. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9 (2): 87–98

    PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article.

Barbara Mintzes has assisted the Canadian Department of Justice with expert testimony in defence of Canada’s prohibition of DTCA, in a legal challenge by CanWest MediaWorks in the Ontario Superior Court. The other authors have no conflicts of interest that are relevant to the content of this article.

Author information

Authors and Affiliations

  1. Women’s and Children’s Hospital, North Adelaide, South Australia, Australia

    Jon Jureidini (Psychiatrist)

  2. Therapeutics Initiative, University of British Columbia, Vancouver, British Columbia, Canada

    Barbara Mintzes

  3. Department of Public Health, Flinders University, Adelaide, South Australia, Australia

    Melissa Raven

Authors
  1. Jon Jureidini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Mintzes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melissa Raven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jon Jureidini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jureidini, J., Mintzes, B. & Raven, M. Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?. Pharmacoeconomics 26, 557–566 (2008). https://doi.org/10.2165/00019053-200826070-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200826070-00003

Keywords

Search

Navigation